Stay updated with breaking news from Antonio Addis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An analysis of clinical studies that compared approved biological drugs with their biosimilar counterparts has failed to find clinically meaningful differences in efficacy and adverse events.
'Switching patients currently on originators to biosimilars could be considered where clinically appropriate to reduce treatment costs,' the authors concluded.
Robust data from clinical trials, cohort studies still lacking